About AMP® Heart Failure

About the Accelerating Medicines Partnership® (AMP®) Program

The Accelerating Medicines Partnership® (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations.

Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. Disease areas covered by AMP at the launch of this site include Alzheimer’s disease, the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus), Parkinson’s disease, common metabolic diseases, Schizophrenia, and rare diseases. AMP HF is the 10th AMP project to be launched. To learn more about all the AMP projects, click here.

About HeartShare

HeartShare is a NIH-funded program to conduct large-scale analysis of phenotypic data, images, and omics from patients with heart failure with preserved ejection fraction (HFpEF) and controls in order to characterize mechanisms of disease and identify therapeutic targets. HeartShare is composed of a Data Translation Center at Northwestern University, which serves as the hub for coordinating the study and integrating all HeartShare data (existing datasets and prospective data), and 6 Clinical Centers (Massachusetts General Hospital/Brigham and Womens Hospital, Mayo Clinic, Northwestern, University of Pennsylvania, University of California-Davis, and Wake Forest University), which conduct the prospective deep phenotyping part of the study (n=1000 patients).

Learn more about the organization and responsibilities of this study from the HeartShare Cohort Consortium Governance Principles.

Patient Resources

NHLBI – Heart Failure: https://www.nhlbi.nih.gov/health/heart-failure

CDC – Facts & Resources: https://www.cdc.gov/heartdisease/heart_failure.htm

HFSA – Facts & Information: https://hfsa.org/patient-hub/heart-failure-facts-information